8 Partial response: 6 Progression: 7 Non assessable: n=3 Death: 1 Major toxicity: 1 Comorbidity: 1 Figure 1 Flow chart of included patients; arm A: DG followed by erlotinib if progression, arm B: erlotinib followed by DG if progression (assessable patient: at least 8 weeks of treatment)...
and as a result theused market for that model has gone crazy. It would make a lot of sense for Fujifilm to rush a successor out ASAP, so as to capitalize on the demand
a) Measurement System b) Goal Type c) Chart Title7.1a) Measurement SystemAt the top of the AdminLists sheet, there is a lookup table for the measurement system.Range D3:D4 is named MeasureList, and that list is used in the drop down on the WeightGoals sheet. Cell D6 shows the ...